Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
31,654
archived clinical trials in
Cardiology

A Phase 2, Multi-Center Study To Compare The Efficacy And Safety Of A Chemokine CCR2/5 Receptor Antagonist With Ranibizumab In Adults With Diabetic Macular Edema
A Phase 2, Randomized, Double-masked, Placebo-controlled, Parallel Group, Multi-center Study To Compare The Efficacy And Safety Of A Chemokine Ccr2/5 Receptor Antagonist (Pf-04634817) With That Of Ranibizumab In Adult Subjects With Diabetic Macular Edema
Status: Enrolling
Updated:  10/8/2015
Retinal Diagnostic Center
mi
from
Campbell, CA
A Phase 2, Multi-Center Study To Compare The Efficacy And Safety Of A Chemokine CCR2/5 Receptor Antagonist With Ranibizumab In Adults With Diabetic Macular Edema
A Phase 2, Randomized, Double-masked, Placebo-controlled, Parallel Group, Multi-center Study To Compare The Efficacy And Safety Of A Chemokine Ccr2/5 Receptor Antagonist (Pf-04634817) With That Of Ranibizumab In Adult Subjects With Diabetic Macular Edema
Status: Enrolling
Updated: 10/8/2015
Retinal Diagnostic Center
mi
from
Campbell, CA
Click here to add this to my saved trials
A Phase 2, Multi-Center Study To Compare The Efficacy And Safety Of A Chemokine CCR2/5 Receptor Antagonist With Ranibizumab In Adults With Diabetic Macular Edema
A Phase 2, Randomized, Double-masked, Placebo-controlled, Parallel Group, Multi-center Study To Compare The Efficacy And Safety Of A Chemokine Ccr2/5 Receptor Antagonist (Pf-04634817) With That Of Ranibizumab In Adult Subjects With Diabetic Macular Edema
Status: Enrolling
Updated:  10/8/2015
Retina Associates of Orange County
mi
from
Laguna Hills, CA
A Phase 2, Multi-Center Study To Compare The Efficacy And Safety Of A Chemokine CCR2/5 Receptor Antagonist With Ranibizumab In Adults With Diabetic Macular Edema
A Phase 2, Randomized, Double-masked, Placebo-controlled, Parallel Group, Multi-center Study To Compare The Efficacy And Safety Of A Chemokine Ccr2/5 Receptor Antagonist (Pf-04634817) With That Of Ranibizumab In Adult Subjects With Diabetic Macular Edema
Status: Enrolling
Updated: 10/8/2015
Retina Associates of Orange County
mi
from
Laguna Hills, CA
Click here to add this to my saved trials
A Phase 2, Multi-Center Study To Compare The Efficacy And Safety Of A Chemokine CCR2/5 Receptor Antagonist With Ranibizumab In Adults With Diabetic Macular Edema
A Phase 2, Randomized, Double-masked, Placebo-controlled, Parallel Group, Multi-center Study To Compare The Efficacy And Safety Of A Chemokine Ccr2/5 Receptor Antagonist (Pf-04634817) With That Of Ranibizumab In Adult Subjects With Diabetic Macular Edema
Status: Enrolling
Updated:  10/8/2015
Southern California Desert Retina Consultants
mi
from
Palm Desert, CA
A Phase 2, Multi-Center Study To Compare The Efficacy And Safety Of A Chemokine CCR2/5 Receptor Antagonist With Ranibizumab In Adults With Diabetic Macular Edema
A Phase 2, Randomized, Double-masked, Placebo-controlled, Parallel Group, Multi-center Study To Compare The Efficacy And Safety Of A Chemokine Ccr2/5 Receptor Antagonist (Pf-04634817) With That Of Ranibizumab In Adult Subjects With Diabetic Macular Edema
Status: Enrolling
Updated: 10/8/2015
Southern California Desert Retina Consultants
mi
from
Palm Desert, CA
Click here to add this to my saved trials
A Phase 2, Multi-Center Study To Compare The Efficacy And Safety Of A Chemokine CCR2/5 Receptor Antagonist With Ranibizumab In Adults With Diabetic Macular Edema
A Phase 2, Randomized, Double-masked, Placebo-controlled, Parallel Group, Multi-center Study To Compare The Efficacy And Safety Of A Chemokine Ccr2/5 Receptor Antagonist (Pf-04634817) With That Of Ranibizumab In Adult Subjects With Diabetic Macular Edema
Status: Enrolling
Updated:  10/8/2015
New England Retina Associates
mi
from
New London, CT
A Phase 2, Multi-Center Study To Compare The Efficacy And Safety Of A Chemokine CCR2/5 Receptor Antagonist With Ranibizumab In Adults With Diabetic Macular Edema
A Phase 2, Randomized, Double-masked, Placebo-controlled, Parallel Group, Multi-center Study To Compare The Efficacy And Safety Of A Chemokine Ccr2/5 Receptor Antagonist (Pf-04634817) With That Of Ranibizumab In Adult Subjects With Diabetic Macular Edema
Status: Enrolling
Updated: 10/8/2015
New England Retina Associates
mi
from
New London, CT
Click here to add this to my saved trials
A Phase 2, Multi-Center Study To Compare The Efficacy And Safety Of A Chemokine CCR2/5 Receptor Antagonist With Ranibizumab In Adults With Diabetic Macular Edema
A Phase 2, Randomized, Double-masked, Placebo-controlled, Parallel Group, Multi-center Study To Compare The Efficacy And Safety Of A Chemokine Ccr2/5 Receptor Antagonist (Pf-04634817) With That Of Ranibizumab In Adult Subjects With Diabetic Macular Edema
Status: Enrolling
Updated:  10/8/2015
Bascom Palmer Eye Institute
mi
from
Miami, FL
A Phase 2, Multi-Center Study To Compare The Efficacy And Safety Of A Chemokine CCR2/5 Receptor Antagonist With Ranibizumab In Adults With Diabetic Macular Edema
A Phase 2, Randomized, Double-masked, Placebo-controlled, Parallel Group, Multi-center Study To Compare The Efficacy And Safety Of A Chemokine Ccr2/5 Receptor Antagonist (Pf-04634817) With That Of Ranibizumab In Adult Subjects With Diabetic Macular Edema
Status: Enrolling
Updated: 10/8/2015
Bascom Palmer Eye Institute
mi
from
Miami, FL
Click here to add this to my saved trials
A Phase 2, Multi-Center Study To Compare The Efficacy And Safety Of A Chemokine CCR2/5 Receptor Antagonist With Ranibizumab In Adults With Diabetic Macular Edema
A Phase 2, Randomized, Double-masked, Placebo-controlled, Parallel Group, Multi-center Study To Compare The Efficacy And Safety Of A Chemokine Ccr2/5 Receptor Antagonist (Pf-04634817) With That Of Ranibizumab In Adult Subjects With Diabetic Macular Edema
Status: Enrolling
Updated:  10/8/2015
Fort Lauderdale Eye Institute
mi
from
Plantation, FL
A Phase 2, Multi-Center Study To Compare The Efficacy And Safety Of A Chemokine CCR2/5 Receptor Antagonist With Ranibizumab In Adults With Diabetic Macular Edema
A Phase 2, Randomized, Double-masked, Placebo-controlled, Parallel Group, Multi-center Study To Compare The Efficacy And Safety Of A Chemokine Ccr2/5 Receptor Antagonist (Pf-04634817) With That Of Ranibizumab In Adult Subjects With Diabetic Macular Edema
Status: Enrolling
Updated: 10/8/2015
Fort Lauderdale Eye Institute
mi
from
Plantation, FL
Click here to add this to my saved trials
A Phase 2, Multi-Center Study To Compare The Efficacy And Safety Of A Chemokine CCR2/5 Receptor Antagonist With Ranibizumab In Adults With Diabetic Macular Edema
A Phase 2, Randomized, Double-masked, Placebo-controlled, Parallel Group, Multi-center Study To Compare The Efficacy And Safety Of A Chemokine Ccr2/5 Receptor Antagonist (Pf-04634817) With That Of Ranibizumab In Adult Subjects With Diabetic Macular Edema
Status: Enrolling
Updated:  10/8/2015
Center for Retina and Macular Disease
mi
from
Winter Haven, FL
A Phase 2, Multi-Center Study To Compare The Efficacy And Safety Of A Chemokine CCR2/5 Receptor Antagonist With Ranibizumab In Adults With Diabetic Macular Edema
A Phase 2, Randomized, Double-masked, Placebo-controlled, Parallel Group, Multi-center Study To Compare The Efficacy And Safety Of A Chemokine Ccr2/5 Receptor Antagonist (Pf-04634817) With That Of Ranibizumab In Adult Subjects With Diabetic Macular Edema
Status: Enrolling
Updated: 10/8/2015
Center for Retina and Macular Disease
mi
from
Winter Haven, FL
Click here to add this to my saved trials
A Phase 2, Multi-Center Study To Compare The Efficacy And Safety Of A Chemokine CCR2/5 Receptor Antagonist With Ranibizumab In Adults With Diabetic Macular Edema
A Phase 2, Randomized, Double-masked, Placebo-controlled, Parallel Group, Multi-center Study To Compare The Efficacy And Safety Of A Chemokine Ccr2/5 Receptor Antagonist (Pf-04634817) With That Of Ranibizumab In Adult Subjects With Diabetic Macular Edema
Status: Enrolling
Updated:  10/8/2015
Southeast Retina Center, P.C.
mi
from
Augusta, GA
A Phase 2, Multi-Center Study To Compare The Efficacy And Safety Of A Chemokine CCR2/5 Receptor Antagonist With Ranibizumab In Adults With Diabetic Macular Edema
A Phase 2, Randomized, Double-masked, Placebo-controlled, Parallel Group, Multi-center Study To Compare The Efficacy And Safety Of A Chemokine Ccr2/5 Receptor Antagonist (Pf-04634817) With That Of Ranibizumab In Adult Subjects With Diabetic Macular Edema
Status: Enrolling
Updated: 10/8/2015
Southeast Retina Center, P.C.
mi
from
Augusta, GA
Click here to add this to my saved trials
A Phase 2, Multi-Center Study To Compare The Efficacy And Safety Of A Chemokine CCR2/5 Receptor Antagonist With Ranibizumab In Adults With Diabetic Macular Edema
A Phase 2, Randomized, Double-masked, Placebo-controlled, Parallel Group, Multi-center Study To Compare The Efficacy And Safety Of A Chemokine Ccr2/5 Receptor Antagonist (Pf-04634817) With That Of Ranibizumab In Adult Subjects With Diabetic Macular Edema
Status: Enrolling
Updated:  10/8/2015
Midwest Eye Institute
mi
from
Indianapolis, IN
A Phase 2, Multi-Center Study To Compare The Efficacy And Safety Of A Chemokine CCR2/5 Receptor Antagonist With Ranibizumab In Adults With Diabetic Macular Edema
A Phase 2, Randomized, Double-masked, Placebo-controlled, Parallel Group, Multi-center Study To Compare The Efficacy And Safety Of A Chemokine Ccr2/5 Receptor Antagonist (Pf-04634817) With That Of Ranibizumab In Adult Subjects With Diabetic Macular Edema
Status: Enrolling
Updated: 10/8/2015
Midwest Eye Institute
mi
from
Indianapolis, IN
Click here to add this to my saved trials
A Phase 2, Multi-Center Study To Compare The Efficacy And Safety Of A Chemokine CCR2/5 Receptor Antagonist With Ranibizumab In Adults With Diabetic Macular Edema
A Phase 2, Randomized, Double-masked, Placebo-controlled, Parallel Group, Multi-center Study To Compare The Efficacy And Safety Of A Chemokine Ccr2/5 Receptor Antagonist (Pf-04634817) With That Of Ranibizumab In Adult Subjects With Diabetic Macular Edema
Status: Enrolling
Updated:  10/8/2015
Tufts Medical Center
mi
from
Boston, MA
A Phase 2, Multi-Center Study To Compare The Efficacy And Safety Of A Chemokine CCR2/5 Receptor Antagonist With Ranibizumab In Adults With Diabetic Macular Edema
A Phase 2, Randomized, Double-masked, Placebo-controlled, Parallel Group, Multi-center Study To Compare The Efficacy And Safety Of A Chemokine Ccr2/5 Receptor Antagonist (Pf-04634817) With That Of Ranibizumab In Adult Subjects With Diabetic Macular Edema
Status: Enrolling
Updated: 10/8/2015
Tufts Medical Center
mi
from
Boston, MA
Click here to add this to my saved trials
A Phase 2, Multi-Center Study To Compare The Efficacy And Safety Of A Chemokine CCR2/5 Receptor Antagonist With Ranibizumab In Adults With Diabetic Macular Edema
A Phase 2, Randomized, Double-masked, Placebo-controlled, Parallel Group, Multi-center Study To Compare The Efficacy And Safety Of A Chemokine Ccr2/5 Receptor Antagonist (Pf-04634817) With That Of Ranibizumab In Adult Subjects With Diabetic Macular Edema
Status: Enrolling
Updated:  10/8/2015
TLC Eyecare and Laser Centers
mi
from
Jackson, MI
A Phase 2, Multi-Center Study To Compare The Efficacy And Safety Of A Chemokine CCR2/5 Receptor Antagonist With Ranibizumab In Adults With Diabetic Macular Edema
A Phase 2, Randomized, Double-masked, Placebo-controlled, Parallel Group, Multi-center Study To Compare The Efficacy And Safety Of A Chemokine Ccr2/5 Receptor Antagonist (Pf-04634817) With That Of Ranibizumab In Adult Subjects With Diabetic Macular Edema
Status: Enrolling
Updated: 10/8/2015
TLC Eyecare and Laser Centers
mi
from
Jackson, MI
Click here to add this to my saved trials
A Phase 2, Multi-Center Study To Compare The Efficacy And Safety Of A Chemokine CCR2/5 Receptor Antagonist With Ranibizumab In Adults With Diabetic Macular Edema
A Phase 2, Randomized, Double-masked, Placebo-controlled, Parallel Group, Multi-center Study To Compare The Efficacy And Safety Of A Chemokine Ccr2/5 Receptor Antagonist (Pf-04634817) With That Of Ranibizumab In Adult Subjects With Diabetic Macular Edema
Status: Enrolling
Updated:  10/8/2015
Associated Retinal Consultants
mi
from
Royal Oak, MI
A Phase 2, Multi-Center Study To Compare The Efficacy And Safety Of A Chemokine CCR2/5 Receptor Antagonist With Ranibizumab In Adults With Diabetic Macular Edema
A Phase 2, Randomized, Double-masked, Placebo-controlled, Parallel Group, Multi-center Study To Compare The Efficacy And Safety Of A Chemokine Ccr2/5 Receptor Antagonist (Pf-04634817) With That Of Ranibizumab In Adult Subjects With Diabetic Macular Edema
Status: Enrolling
Updated: 10/8/2015
Associated Retinal Consultants
mi
from
Royal Oak, MI
Click here to add this to my saved trials
A Phase 2, Multi-Center Study To Compare The Efficacy And Safety Of A Chemokine CCR2/5 Receptor Antagonist With Ranibizumab In Adults With Diabetic Macular Edema
A Phase 2, Randomized, Double-masked, Placebo-controlled, Parallel Group, Multi-center Study To Compare The Efficacy And Safety Of A Chemokine Ccr2/5 Receptor Antagonist (Pf-04634817) With That Of Ranibizumab In Adult Subjects With Diabetic Macular Edema
Status: Enrolling
Updated:  10/8/2015
Charlotte Eye, Ear, Nose & Throat Associates
mi
from
Charlotte, NC
A Phase 2, Multi-Center Study To Compare The Efficacy And Safety Of A Chemokine CCR2/5 Receptor Antagonist With Ranibizumab In Adults With Diabetic Macular Edema
A Phase 2, Randomized, Double-masked, Placebo-controlled, Parallel Group, Multi-center Study To Compare The Efficacy And Safety Of A Chemokine Ccr2/5 Receptor Antagonist (Pf-04634817) With That Of Ranibizumab In Adult Subjects With Diabetic Macular Edema
Status: Enrolling
Updated: 10/8/2015
Charlotte Eye, Ear, Nose & Throat Associates
mi
from
Charlotte, NC
Click here to add this to my saved trials
A Phase 2, Multi-Center Study To Compare The Efficacy And Safety Of A Chemokine CCR2/5 Receptor Antagonist With Ranibizumab In Adults With Diabetic Macular Edema
A Phase 2, Randomized, Double-masked, Placebo-controlled, Parallel Group, Multi-center Study To Compare The Efficacy And Safety Of A Chemokine Ccr2/5 Receptor Antagonist (Pf-04634817) With That Of Ranibizumab In Adult Subjects With Diabetic Macular Edema
Status: Enrolling
Updated:  10/8/2015
Retina Associates of Cleveland
mi
from
Cleveland, OH
A Phase 2, Multi-Center Study To Compare The Efficacy And Safety Of A Chemokine CCR2/5 Receptor Antagonist With Ranibizumab In Adults With Diabetic Macular Edema
A Phase 2, Randomized, Double-masked, Placebo-controlled, Parallel Group, Multi-center Study To Compare The Efficacy And Safety Of A Chemokine Ccr2/5 Receptor Antagonist (Pf-04634817) With That Of Ranibizumab In Adult Subjects With Diabetic Macular Edema
Status: Enrolling
Updated: 10/8/2015
Retina Associates of Cleveland
mi
from
Cleveland, OH
Click here to add this to my saved trials
A Phase 2, Multi-Center Study To Compare The Efficacy And Safety Of A Chemokine CCR2/5 Receptor Antagonist With Ranibizumab In Adults With Diabetic Macular Edema
A Phase 2, Randomized, Double-masked, Placebo-controlled, Parallel Group, Multi-center Study To Compare The Efficacy And Safety Of A Chemokine Ccr2/5 Receptor Antagonist (Pf-04634817) With That Of Ranibizumab In Adult Subjects With Diabetic Macular Edema
Status: Enrolling
Updated:  10/8/2015
Retina Associates of Cleveland
mi
from
Youngstown, OH
A Phase 2, Multi-Center Study To Compare The Efficacy And Safety Of A Chemokine CCR2/5 Receptor Antagonist With Ranibizumab In Adults With Diabetic Macular Edema
A Phase 2, Randomized, Double-masked, Placebo-controlled, Parallel Group, Multi-center Study To Compare The Efficacy And Safety Of A Chemokine Ccr2/5 Receptor Antagonist (Pf-04634817) With That Of Ranibizumab In Adult Subjects With Diabetic Macular Edema
Status: Enrolling
Updated: 10/8/2015
Retina Associates of Cleveland
mi
from
Youngstown, OH
Click here to add this to my saved trials
A Phase 2, Multi-Center Study To Compare The Efficacy And Safety Of A Chemokine CCR2/5 Receptor Antagonist With Ranibizumab In Adults With Diabetic Macular Edema
A Phase 2, Randomized, Double-masked, Placebo-controlled, Parallel Group, Multi-center Study To Compare The Efficacy And Safety Of A Chemokine Ccr2/5 Receptor Antagonist (Pf-04634817) With That Of Ranibizumab In Adult Subjects With Diabetic Macular Edema
Status: Enrolling
Updated:  10/8/2015
Dean McGee Eye Institute
mi
from
Oklahoma City, OK
A Phase 2, Multi-Center Study To Compare The Efficacy And Safety Of A Chemokine CCR2/5 Receptor Antagonist With Ranibizumab In Adults With Diabetic Macular Edema
A Phase 2, Randomized, Double-masked, Placebo-controlled, Parallel Group, Multi-center Study To Compare The Efficacy And Safety Of A Chemokine Ccr2/5 Receptor Antagonist (Pf-04634817) With That Of Ranibizumab In Adult Subjects With Diabetic Macular Edema
Status: Enrolling
Updated: 10/8/2015
Dean McGee Eye Institute
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
A Phase 2, Multi-Center Study To Compare The Efficacy And Safety Of A Chemokine CCR2/5 Receptor Antagonist With Ranibizumab In Adults With Diabetic Macular Edema
A Phase 2, Randomized, Double-masked, Placebo-controlled, Parallel Group, Multi-center Study To Compare The Efficacy And Safety Of A Chemokine Ccr2/5 Receptor Antagonist (Pf-04634817) With That Of Ranibizumab In Adult Subjects With Diabetic Macular Edema
Status: Enrolling
Updated:  10/8/2015
Retina Vitreous Consultants
mi
from
Pittsburgh, PA
A Phase 2, Multi-Center Study To Compare The Efficacy And Safety Of A Chemokine CCR2/5 Receptor Antagonist With Ranibizumab In Adults With Diabetic Macular Edema
A Phase 2, Randomized, Double-masked, Placebo-controlled, Parallel Group, Multi-center Study To Compare The Efficacy And Safety Of A Chemokine Ccr2/5 Receptor Antagonist (Pf-04634817) With That Of Ranibizumab In Adult Subjects With Diabetic Macular Edema
Status: Enrolling
Updated: 10/8/2015
Retina Vitreous Consultants
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
A Phase 2, Multi-Center Study To Compare The Efficacy And Safety Of A Chemokine CCR2/5 Receptor Antagonist With Ranibizumab In Adults With Diabetic Macular Edema
A Phase 2, Randomized, Double-masked, Placebo-controlled, Parallel Group, Multi-center Study To Compare The Efficacy And Safety Of A Chemokine Ccr2/5 Receptor Antagonist (Pf-04634817) With That Of Ranibizumab In Adult Subjects With Diabetic Macular Edema
Status: Enrolling
Updated:  10/8/2015
Associates in Ophthalmology
mi
from
West Mifflin, PA
A Phase 2, Multi-Center Study To Compare The Efficacy And Safety Of A Chemokine CCR2/5 Receptor Antagonist With Ranibizumab In Adults With Diabetic Macular Edema
A Phase 2, Randomized, Double-masked, Placebo-controlled, Parallel Group, Multi-center Study To Compare The Efficacy And Safety Of A Chemokine Ccr2/5 Receptor Antagonist (Pf-04634817) With That Of Ranibizumab In Adult Subjects With Diabetic Macular Edema
Status: Enrolling
Updated: 10/8/2015
Associates in Ophthalmology
mi
from
West Mifflin, PA
Click here to add this to my saved trials
A Phase 2, Multi-Center Study To Compare The Efficacy And Safety Of A Chemokine CCR2/5 Receptor Antagonist With Ranibizumab In Adults With Diabetic Macular Edema
A Phase 2, Randomized, Double-masked, Placebo-controlled, Parallel Group, Multi-center Study To Compare The Efficacy And Safety Of A Chemokine Ccr2/5 Receptor Antagonist (Pf-04634817) With That Of Ranibizumab In Adult Subjects With Diabetic Macular Edema
Status: Enrolling
Updated:  10/8/2015
Black Hills Regional Eye Institute
mi
from
Rapid City, SD
A Phase 2, Multi-Center Study To Compare The Efficacy And Safety Of A Chemokine CCR2/5 Receptor Antagonist With Ranibizumab In Adults With Diabetic Macular Edema
A Phase 2, Randomized, Double-masked, Placebo-controlled, Parallel Group, Multi-center Study To Compare The Efficacy And Safety Of A Chemokine Ccr2/5 Receptor Antagonist (Pf-04634817) With That Of Ranibizumab In Adult Subjects With Diabetic Macular Edema
Status: Enrolling
Updated: 10/8/2015
Black Hills Regional Eye Institute
mi
from
Rapid City, SD
Click here to add this to my saved trials
A Phase 2, Multi-Center Study To Compare The Efficacy And Safety Of A Chemokine CCR2/5 Receptor Antagonist With Ranibizumab In Adults With Diabetic Macular Edema
A Phase 2, Randomized, Double-masked, Placebo-controlled, Parallel Group, Multi-center Study To Compare The Efficacy And Safety Of A Chemokine Ccr2/5 Receptor Antagonist (Pf-04634817) With That Of Ranibizumab In Adult Subjects With Diabetic Macular Edema
Status: Enrolling
Updated:  10/8/2015
Retina Research Center
mi
from
Austin, TX
A Phase 2, Multi-Center Study To Compare The Efficacy And Safety Of A Chemokine CCR2/5 Receptor Antagonist With Ranibizumab In Adults With Diabetic Macular Edema
A Phase 2, Randomized, Double-masked, Placebo-controlled, Parallel Group, Multi-center Study To Compare The Efficacy And Safety Of A Chemokine Ccr2/5 Receptor Antagonist (Pf-04634817) With That Of Ranibizumab In Adult Subjects With Diabetic Macular Edema
Status: Enrolling
Updated: 10/8/2015
Retina Research Center
mi
from
Austin, TX
Click here to add this to my saved trials
A Phase 2, Multi-Center Study To Compare The Efficacy And Safety Of A Chemokine CCR2/5 Receptor Antagonist With Ranibizumab In Adults With Diabetic Macular Edema
A Phase 2, Randomized, Double-masked, Placebo-controlled, Parallel Group, Multi-center Study To Compare The Efficacy And Safety Of A Chemokine Ccr2/5 Receptor Antagonist (Pf-04634817) With That Of Ranibizumab In Adult Subjects With Diabetic Macular Edema
Status: Enrolling
Updated:  10/8/2015
Retina Consultants of Houston
mi
from
Houston, TX
A Phase 2, Multi-Center Study To Compare The Efficacy And Safety Of A Chemokine CCR2/5 Receptor Antagonist With Ranibizumab In Adults With Diabetic Macular Edema
A Phase 2, Randomized, Double-masked, Placebo-controlled, Parallel Group, Multi-center Study To Compare The Efficacy And Safety Of A Chemokine Ccr2/5 Receptor Antagonist (Pf-04634817) With That Of Ranibizumab In Adult Subjects With Diabetic Macular Edema
Status: Enrolling
Updated: 10/8/2015
Retina Consultants of Houston
mi
from
Houston, TX
Click here to add this to my saved trials
A Phase 2, Multi-Center Study To Compare The Efficacy And Safety Of A Chemokine CCR2/5 Receptor Antagonist With Ranibizumab In Adults With Diabetic Macular Edema
A Phase 2, Randomized, Double-masked, Placebo-controlled, Parallel Group, Multi-center Study To Compare The Efficacy And Safety Of A Chemokine Ccr2/5 Receptor Antagonist (Pf-04634817) With That Of Ranibizumab In Adult Subjects With Diabetic Macular Edema
Status: Enrolling
Updated:  10/8/2015
Medical Center Ophthalmology Associates
mi
from
San Antonio, TX
A Phase 2, Multi-Center Study To Compare The Efficacy And Safety Of A Chemokine CCR2/5 Receptor Antagonist With Ranibizumab In Adults With Diabetic Macular Edema
A Phase 2, Randomized, Double-masked, Placebo-controlled, Parallel Group, Multi-center Study To Compare The Efficacy And Safety Of A Chemokine Ccr2/5 Receptor Antagonist (Pf-04634817) With That Of Ranibizumab In Adult Subjects With Diabetic Macular Edema
Status: Enrolling
Updated: 10/8/2015
Medical Center Ophthalmology Associates
mi
from
San Antonio, TX
Click here to add this to my saved trials
A Phase 2, Multi-Center Study To Compare The Efficacy And Safety Of A Chemokine CCR2/5 Receptor Antagonist With Ranibizumab In Adults With Diabetic Macular Edema
A Phase 2, Randomized, Double-masked, Placebo-controlled, Parallel Group, Multi-center Study To Compare The Efficacy And Safety Of A Chemokine Ccr2/5 Receptor Antagonist (Pf-04634817) With That Of Ranibizumab In Adult Subjects With Diabetic Macular Edema
Status: Enrolling
Updated:  10/8/2015
Rocky Mountain Retina Consultants
mi
from
Salt Lake City, UT
A Phase 2, Multi-Center Study To Compare The Efficacy And Safety Of A Chemokine CCR2/5 Receptor Antagonist With Ranibizumab In Adults With Diabetic Macular Edema
A Phase 2, Randomized, Double-masked, Placebo-controlled, Parallel Group, Multi-center Study To Compare The Efficacy And Safety Of A Chemokine Ccr2/5 Receptor Antagonist (Pf-04634817) With That Of Ranibizumab In Adult Subjects With Diabetic Macular Edema
Status: Enrolling
Updated: 10/8/2015
Rocky Mountain Retina Consultants
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
A Phase 2, Multi-Center Study To Compare The Efficacy And Safety Of A Chemokine CCR2/5 Receptor Antagonist With Ranibizumab In Adults With Diabetic Macular Edema
A Phase 2, Randomized, Double-masked, Placebo-controlled, Parallel Group, Multi-center Study To Compare The Efficacy And Safety Of A Chemokine Ccr2/5 Receptor Antagonist (Pf-04634817) With That Of Ranibizumab In Adult Subjects With Diabetic Macular Edema
Status: Enrolling
Updated:  10/8/2015
MC Comac Medical
mi
from
Sofia,
A Phase 2, Multi-Center Study To Compare The Efficacy And Safety Of A Chemokine CCR2/5 Receptor Antagonist With Ranibizumab In Adults With Diabetic Macular Edema
A Phase 2, Randomized, Double-masked, Placebo-controlled, Parallel Group, Multi-center Study To Compare The Efficacy And Safety Of A Chemokine Ccr2/5 Receptor Antagonist (Pf-04634817) With That Of Ranibizumab In Adult Subjects With Diabetic Macular Edema
Status: Enrolling
Updated: 10/8/2015
MC Comac Medical
mi
from
Sofia,
Click here to add this to my saved trials
Dissolved Oxygen Dressing to Improve Chronic Wound Healing After Revascularization for Critical Limb Ischemia
A Prospective, Randomized, Single-center Pilot Study of the OxyGenesys™ Dissolved Oxygen Dressing to Improve Chronic Wound Healing After Revascularization for Critical Limb Ischemia
Status: Enrolling
Updated:  10/8/2015
Yale-New Haven Hospital
mi
from
New Haven, CT
Dissolved Oxygen Dressing to Improve Chronic Wound Healing After Revascularization for Critical Limb Ischemia
A Prospective, Randomized, Single-center Pilot Study of the OxyGenesys™ Dissolved Oxygen Dressing to Improve Chronic Wound Healing After Revascularization for Critical Limb Ischemia
Status: Enrolling
Updated: 10/8/2015
Yale-New Haven Hospital
mi
from
New Haven, CT
Click here to add this to my saved trials
Barrow Ruptured Aneurysm Trial
Barrow Ruptured Aneurysm Study
Status: Enrolling
Updated:  10/8/2015
St. Joseph's Hospital and Medical Center
mi
from
Phoenix, AZ
Barrow Ruptured Aneurysm Trial
Barrow Ruptured Aneurysm Study
Status: Enrolling
Updated: 10/8/2015
St. Joseph's Hospital and Medical Center
mi
from
Phoenix, AZ
Click here to add this to my saved trials
ATS 3f(r) Aortic Bioprosthesis Model 1000, 19mm
ATS 3f(r) Aortic Bioprosthesis Model 1000
Status: Enrolling
Updated:  10/9/2015
The Lankenau Institute for Medical Research
mi
from
Wynnewood, PA
ATS 3f(r) Aortic Bioprosthesis Model 1000, 19mm
ATS 3f(r) Aortic Bioprosthesis Model 1000
Status: Enrolling
Updated: 10/9/2015
The Lankenau Institute for Medical Research
mi
from
Wynnewood, PA
Click here to add this to my saved trials
ATS 3f(r) Aortic Bioprosthesis Model 1000, 19mm
ATS 3f(r) Aortic Bioprosthesis Model 1000
Status: Enrolling
Updated:  10/9/2015
McGill University Health Centre
mi
from
Montreal,
ATS 3f(r) Aortic Bioprosthesis Model 1000, 19mm
ATS 3f(r) Aortic Bioprosthesis Model 1000
Status: Enrolling
Updated: 10/9/2015
McGill University Health Centre
mi
from
Montreal,
Click here to add this to my saved trials
Effects of Sitagliptin on Endothelial Function in Type 2 Diabetes on Background Metformin Therapy
A Randomized, Crossover Design Study of Acute and Chronic Effects of Sitagliptin on Endothelial Function in Humans With Type 2 Diabetes on Background Metformin
Status: Enrolling
Updated:  10/9/2015
Medical College of Wisconsin
mi
from
Milwaukee, WI
Effects of Sitagliptin on Endothelial Function in Type 2 Diabetes on Background Metformin Therapy
A Randomized, Crossover Design Study of Acute and Chronic Effects of Sitagliptin on Endothelial Function in Humans With Type 2 Diabetes on Background Metformin
Status: Enrolling
Updated: 10/9/2015
Medical College of Wisconsin
mi
from
Milwaukee, WI
Click here to add this to my saved trials
Effects of Sitagliptin on Endothelial Function in Type 2 Diabetes on Background Metformin Therapy
A Randomized, Crossover Design Study of Acute and Chronic Effects of Sitagliptin on Endothelial Function in Humans With Type 2 Diabetes on Background Metformin
Status: Enrolling
Updated:  10/9/2015
Medical College of Wisconsin
mi
from
Milwaukee, WI
Effects of Sitagliptin on Endothelial Function in Type 2 Diabetes on Background Metformin Therapy
A Randomized, Crossover Design Study of Acute and Chronic Effects of Sitagliptin on Endothelial Function in Humans With Type 2 Diabetes on Background Metformin
Status: Enrolling
Updated: 10/9/2015
Medical College of Wisconsin
mi
from
Milwaukee, WI
Click here to add this to my saved trials
Phase IIb Safety and Efficacy Study of Four Dose Regimens of BAY1021189 in Patients With Heart Failure and Preserved Ejection Fraction Suffering From Worsening Chronic Heart Failure (SOCRATES-PRESERVED)
A Randomized Parallel-group, Placebo-controlled, Double-blind, Multi-center Dose Finding Phase II Trial Exploring the Pharmacodynamic Effects, Safety and Tolerability, and Pharmacokinetics of Four Dose Regimens of the Oral sGC Stimulator BAY1021189 Over 12 Weeks in Patients With Worsening Heart Failure and Preserved Ejection Fraction (HFpEF)
Status: Enrolling
Updated:  10/9/2015
Clinical Research Facility
mi
from
Fountain Valley, CA
Phase IIb Safety and Efficacy Study of Four Dose Regimens of BAY1021189 in Patients With Heart Failure and Preserved Ejection Fraction Suffering From Worsening Chronic Heart Failure (SOCRATES-PRESERVED)
A Randomized Parallel-group, Placebo-controlled, Double-blind, Multi-center Dose Finding Phase II Trial Exploring the Pharmacodynamic Effects, Safety and Tolerability, and Pharmacokinetics of Four Dose Regimens of the Oral sGC Stimulator BAY1021189 Over 12 Weeks in Patients With Worsening Heart Failure and Preserved Ejection Fraction (HFpEF)
Status: Enrolling
Updated: 10/9/2015
Clinical Research Facility
mi
from
Fountain Valley, CA
Click here to add this to my saved trials
Phase IIb Safety and Efficacy Study of Four Dose Regimens of BAY1021189 in Patients With Heart Failure and Preserved Ejection Fraction Suffering From Worsening Chronic Heart Failure (SOCRATES-PRESERVED)
A Randomized Parallel-group, Placebo-controlled, Double-blind, Multi-center Dose Finding Phase II Trial Exploring the Pharmacodynamic Effects, Safety and Tolerability, and Pharmacokinetics of Four Dose Regimens of the Oral sGC Stimulator BAY1021189 Over 12 Weeks in Patients With Worsening Heart Failure and Preserved Ejection Fraction (HFpEF)
Status: Enrolling
Updated:  10/9/2015
Clinical Research Facility
mi
from
La Jolla, CA
Phase IIb Safety and Efficacy Study of Four Dose Regimens of BAY1021189 in Patients With Heart Failure and Preserved Ejection Fraction Suffering From Worsening Chronic Heart Failure (SOCRATES-PRESERVED)
A Randomized Parallel-group, Placebo-controlled, Double-blind, Multi-center Dose Finding Phase II Trial Exploring the Pharmacodynamic Effects, Safety and Tolerability, and Pharmacokinetics of Four Dose Regimens of the Oral sGC Stimulator BAY1021189 Over 12 Weeks in Patients With Worsening Heart Failure and Preserved Ejection Fraction (HFpEF)
Status: Enrolling
Updated: 10/9/2015
Clinical Research Facility
mi
from
La Jolla, CA
Click here to add this to my saved trials
Phase IIb Safety and Efficacy Study of Four Dose Regimens of BAY1021189 in Patients With Heart Failure and Preserved Ejection Fraction Suffering From Worsening Chronic Heart Failure (SOCRATES-PRESERVED)
A Randomized Parallel-group, Placebo-controlled, Double-blind, Multi-center Dose Finding Phase II Trial Exploring the Pharmacodynamic Effects, Safety and Tolerability, and Pharmacokinetics of Four Dose Regimens of the Oral sGC Stimulator BAY1021189 Over 12 Weeks in Patients With Worsening Heart Failure and Preserved Ejection Fraction (HFpEF)
Status: Enrolling
Updated:  10/9/2015
Clinical Research Facility
mi
from
Los Angeles, CA
Phase IIb Safety and Efficacy Study of Four Dose Regimens of BAY1021189 in Patients With Heart Failure and Preserved Ejection Fraction Suffering From Worsening Chronic Heart Failure (SOCRATES-PRESERVED)
A Randomized Parallel-group, Placebo-controlled, Double-blind, Multi-center Dose Finding Phase II Trial Exploring the Pharmacodynamic Effects, Safety and Tolerability, and Pharmacokinetics of Four Dose Regimens of the Oral sGC Stimulator BAY1021189 Over 12 Weeks in Patients With Worsening Heart Failure and Preserved Ejection Fraction (HFpEF)
Status: Enrolling
Updated: 10/9/2015
Clinical Research Facility
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Phase IIb Safety and Efficacy Study of Four Dose Regimens of BAY1021189 in Patients With Heart Failure and Preserved Ejection Fraction Suffering From Worsening Chronic Heart Failure (SOCRATES-PRESERVED)
A Randomized Parallel-group, Placebo-controlled, Double-blind, Multi-center Dose Finding Phase II Trial Exploring the Pharmacodynamic Effects, Safety and Tolerability, and Pharmacokinetics of Four Dose Regimens of the Oral sGC Stimulator BAY1021189 Over 12 Weeks in Patients With Worsening Heart Failure and Preserved Ejection Fraction (HFpEF)
Status: Enrolling
Updated:  10/9/2015
Clinical Research Facility
mi
from
Wilmington, DE
Phase IIb Safety and Efficacy Study of Four Dose Regimens of BAY1021189 in Patients With Heart Failure and Preserved Ejection Fraction Suffering From Worsening Chronic Heart Failure (SOCRATES-PRESERVED)
A Randomized Parallel-group, Placebo-controlled, Double-blind, Multi-center Dose Finding Phase II Trial Exploring the Pharmacodynamic Effects, Safety and Tolerability, and Pharmacokinetics of Four Dose Regimens of the Oral sGC Stimulator BAY1021189 Over 12 Weeks in Patients With Worsening Heart Failure and Preserved Ejection Fraction (HFpEF)
Status: Enrolling
Updated: 10/9/2015
Clinical Research Facility
mi
from
Wilmington, DE
Click here to add this to my saved trials
Phase IIb Safety and Efficacy Study of Four Dose Regimens of BAY1021189 in Patients With Heart Failure and Preserved Ejection Fraction Suffering From Worsening Chronic Heart Failure (SOCRATES-PRESERVED)
A Randomized Parallel-group, Placebo-controlled, Double-blind, Multi-center Dose Finding Phase II Trial Exploring the Pharmacodynamic Effects, Safety and Tolerability, and Pharmacokinetics of Four Dose Regimens of the Oral sGC Stimulator BAY1021189 Over 12 Weeks in Patients With Worsening Heart Failure and Preserved Ejection Fraction (HFpEF)
Status: Enrolling
Updated:  10/9/2015
Clinical Research Facility
mi
from
Ft. Lauderdale, FL
Phase IIb Safety and Efficacy Study of Four Dose Regimens of BAY1021189 in Patients With Heart Failure and Preserved Ejection Fraction Suffering From Worsening Chronic Heart Failure (SOCRATES-PRESERVED)
A Randomized Parallel-group, Placebo-controlled, Double-blind, Multi-center Dose Finding Phase II Trial Exploring the Pharmacodynamic Effects, Safety and Tolerability, and Pharmacokinetics of Four Dose Regimens of the Oral sGC Stimulator BAY1021189 Over 12 Weeks in Patients With Worsening Heart Failure and Preserved Ejection Fraction (HFpEF)
Status: Enrolling
Updated: 10/9/2015
Clinical Research Facility
mi
from
Ft. Lauderdale, FL
Click here to add this to my saved trials
Phase IIb Safety and Efficacy Study of Four Dose Regimens of BAY1021189 in Patients With Heart Failure and Preserved Ejection Fraction Suffering From Worsening Chronic Heart Failure (SOCRATES-PRESERVED)
A Randomized Parallel-group, Placebo-controlled, Double-blind, Multi-center Dose Finding Phase II Trial Exploring the Pharmacodynamic Effects, Safety and Tolerability, and Pharmacokinetics of Four Dose Regimens of the Oral sGC Stimulator BAY1021189 Over 12 Weeks in Patients With Worsening Heart Failure and Preserved Ejection Fraction (HFpEF)
Status: Enrolling
Updated:  10/9/2015
Clinical Research Facility
mi
from
Jacksonville, FL
Phase IIb Safety and Efficacy Study of Four Dose Regimens of BAY1021189 in Patients With Heart Failure and Preserved Ejection Fraction Suffering From Worsening Chronic Heart Failure (SOCRATES-PRESERVED)
A Randomized Parallel-group, Placebo-controlled, Double-blind, Multi-center Dose Finding Phase II Trial Exploring the Pharmacodynamic Effects, Safety and Tolerability, and Pharmacokinetics of Four Dose Regimens of the Oral sGC Stimulator BAY1021189 Over 12 Weeks in Patients With Worsening Heart Failure and Preserved Ejection Fraction (HFpEF)
Status: Enrolling
Updated: 10/9/2015
Clinical Research Facility
mi
from
Jacksonville, FL
Click here to add this to my saved trials
Phase IIb Safety and Efficacy Study of Four Dose Regimens of BAY1021189 in Patients With Heart Failure and Preserved Ejection Fraction Suffering From Worsening Chronic Heart Failure (SOCRATES-PRESERVED)
A Randomized Parallel-group, Placebo-controlled, Double-blind, Multi-center Dose Finding Phase II Trial Exploring the Pharmacodynamic Effects, Safety and Tolerability, and Pharmacokinetics of Four Dose Regimens of the Oral sGC Stimulator BAY1021189 Over 12 Weeks in Patients With Worsening Heart Failure and Preserved Ejection Fraction (HFpEF)
Status: Enrolling
Updated:  10/9/2015
Clinical Research Facility
mi
from
Naples, FL
Phase IIb Safety and Efficacy Study of Four Dose Regimens of BAY1021189 in Patients With Heart Failure and Preserved Ejection Fraction Suffering From Worsening Chronic Heart Failure (SOCRATES-PRESERVED)
A Randomized Parallel-group, Placebo-controlled, Double-blind, Multi-center Dose Finding Phase II Trial Exploring the Pharmacodynamic Effects, Safety and Tolerability, and Pharmacokinetics of Four Dose Regimens of the Oral sGC Stimulator BAY1021189 Over 12 Weeks in Patients With Worsening Heart Failure and Preserved Ejection Fraction (HFpEF)
Status: Enrolling
Updated: 10/9/2015
Clinical Research Facility
mi
from
Naples, FL
Click here to add this to my saved trials
Phase IIb Safety and Efficacy Study of Four Dose Regimens of BAY1021189 in Patients With Heart Failure and Preserved Ejection Fraction Suffering From Worsening Chronic Heart Failure (SOCRATES-PRESERVED)
A Randomized Parallel-group, Placebo-controlled, Double-blind, Multi-center Dose Finding Phase II Trial Exploring the Pharmacodynamic Effects, Safety and Tolerability, and Pharmacokinetics of Four Dose Regimens of the Oral sGC Stimulator BAY1021189 Over 12 Weeks in Patients With Worsening Heart Failure and Preserved Ejection Fraction (HFpEF)
Status: Enrolling
Updated:  10/9/2015
Clinical Research Facility
mi
from
Atlanta, GA
Phase IIb Safety and Efficacy Study of Four Dose Regimens of BAY1021189 in Patients With Heart Failure and Preserved Ejection Fraction Suffering From Worsening Chronic Heart Failure (SOCRATES-PRESERVED)
A Randomized Parallel-group, Placebo-controlled, Double-blind, Multi-center Dose Finding Phase II Trial Exploring the Pharmacodynamic Effects, Safety and Tolerability, and Pharmacokinetics of Four Dose Regimens of the Oral sGC Stimulator BAY1021189 Over 12 Weeks in Patients With Worsening Heart Failure and Preserved Ejection Fraction (HFpEF)
Status: Enrolling
Updated: 10/9/2015
Clinical Research Facility
mi
from
Atlanta, GA
Click here to add this to my saved trials
Phase IIb Safety and Efficacy Study of Four Dose Regimens of BAY1021189 in Patients With Heart Failure and Preserved Ejection Fraction Suffering From Worsening Chronic Heart Failure (SOCRATES-PRESERVED)
A Randomized Parallel-group, Placebo-controlled, Double-blind, Multi-center Dose Finding Phase II Trial Exploring the Pharmacodynamic Effects, Safety and Tolerability, and Pharmacokinetics of Four Dose Regimens of the Oral sGC Stimulator BAY1021189 Over 12 Weeks in Patients With Worsening Heart Failure and Preserved Ejection Fraction (HFpEF)
Status: Enrolling
Updated:  10/9/2015
Clinical Research Facility
mi
from
Macon, GA
Phase IIb Safety and Efficacy Study of Four Dose Regimens of BAY1021189 in Patients With Heart Failure and Preserved Ejection Fraction Suffering From Worsening Chronic Heart Failure (SOCRATES-PRESERVED)
A Randomized Parallel-group, Placebo-controlled, Double-blind, Multi-center Dose Finding Phase II Trial Exploring the Pharmacodynamic Effects, Safety and Tolerability, and Pharmacokinetics of Four Dose Regimens of the Oral sGC Stimulator BAY1021189 Over 12 Weeks in Patients With Worsening Heart Failure and Preserved Ejection Fraction (HFpEF)
Status: Enrolling
Updated: 10/9/2015
Clinical Research Facility
mi
from
Macon, GA
Click here to add this to my saved trials
Phase IIb Safety and Efficacy Study of Four Dose Regimens of BAY1021189 in Patients With Heart Failure and Preserved Ejection Fraction Suffering From Worsening Chronic Heart Failure (SOCRATES-PRESERVED)
A Randomized Parallel-group, Placebo-controlled, Double-blind, Multi-center Dose Finding Phase II Trial Exploring the Pharmacodynamic Effects, Safety and Tolerability, and Pharmacokinetics of Four Dose Regimens of the Oral sGC Stimulator BAY1021189 Over 12 Weeks in Patients With Worsening Heart Failure and Preserved Ejection Fraction (HFpEF)
Status: Enrolling
Updated:  10/9/2015
Clinical Research Facility
mi
from
Chicago, IL
Phase IIb Safety and Efficacy Study of Four Dose Regimens of BAY1021189 in Patients With Heart Failure and Preserved Ejection Fraction Suffering From Worsening Chronic Heart Failure (SOCRATES-PRESERVED)
A Randomized Parallel-group, Placebo-controlled, Double-blind, Multi-center Dose Finding Phase II Trial Exploring the Pharmacodynamic Effects, Safety and Tolerability, and Pharmacokinetics of Four Dose Regimens of the Oral sGC Stimulator BAY1021189 Over 12 Weeks in Patients With Worsening Heart Failure and Preserved Ejection Fraction (HFpEF)
Status: Enrolling
Updated: 10/9/2015
Clinical Research Facility
mi
from
Chicago, IL
Click here to add this to my saved trials
Phase IIb Safety and Efficacy Study of Four Dose Regimens of BAY1021189 in Patients With Heart Failure and Preserved Ejection Fraction Suffering From Worsening Chronic Heart Failure (SOCRATES-PRESERVED)
A Randomized Parallel-group, Placebo-controlled, Double-blind, Multi-center Dose Finding Phase II Trial Exploring the Pharmacodynamic Effects, Safety and Tolerability, and Pharmacokinetics of Four Dose Regimens of the Oral sGC Stimulator BAY1021189 Over 12 Weeks in Patients With Worsening Heart Failure and Preserved Ejection Fraction (HFpEF)
Status: Enrolling
Updated:  10/9/2015
Clinical Research Facility
mi
from
Indianapolis, IN
Phase IIb Safety and Efficacy Study of Four Dose Regimens of BAY1021189 in Patients With Heart Failure and Preserved Ejection Fraction Suffering From Worsening Chronic Heart Failure (SOCRATES-PRESERVED)
A Randomized Parallel-group, Placebo-controlled, Double-blind, Multi-center Dose Finding Phase II Trial Exploring the Pharmacodynamic Effects, Safety and Tolerability, and Pharmacokinetics of Four Dose Regimens of the Oral sGC Stimulator BAY1021189 Over 12 Weeks in Patients With Worsening Heart Failure and Preserved Ejection Fraction (HFpEF)
Status: Enrolling
Updated: 10/9/2015
Clinical Research Facility
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Phase IIb Safety and Efficacy Study of Four Dose Regimens of BAY1021189 in Patients With Heart Failure and Preserved Ejection Fraction Suffering From Worsening Chronic Heart Failure (SOCRATES-PRESERVED)
A Randomized Parallel-group, Placebo-controlled, Double-blind, Multi-center Dose Finding Phase II Trial Exploring the Pharmacodynamic Effects, Safety and Tolerability, and Pharmacokinetics of Four Dose Regimens of the Oral sGC Stimulator BAY1021189 Over 12 Weeks in Patients With Worsening Heart Failure and Preserved Ejection Fraction (HFpEF)
Status: Enrolling
Updated:  10/9/2015
Clinical Research Facility
mi
from
Iowa City, IA
Phase IIb Safety and Efficacy Study of Four Dose Regimens of BAY1021189 in Patients With Heart Failure and Preserved Ejection Fraction Suffering From Worsening Chronic Heart Failure (SOCRATES-PRESERVED)
A Randomized Parallel-group, Placebo-controlled, Double-blind, Multi-center Dose Finding Phase II Trial Exploring the Pharmacodynamic Effects, Safety and Tolerability, and Pharmacokinetics of Four Dose Regimens of the Oral sGC Stimulator BAY1021189 Over 12 Weeks in Patients With Worsening Heart Failure and Preserved Ejection Fraction (HFpEF)
Status: Enrolling
Updated: 10/9/2015
Clinical Research Facility
mi
from
Iowa City, IA
Click here to add this to my saved trials
Phase IIb Safety and Efficacy Study of Four Dose Regimens of BAY1021189 in Patients With Heart Failure and Preserved Ejection Fraction Suffering From Worsening Chronic Heart Failure (SOCRATES-PRESERVED)
A Randomized Parallel-group, Placebo-controlled, Double-blind, Multi-center Dose Finding Phase II Trial Exploring the Pharmacodynamic Effects, Safety and Tolerability, and Pharmacokinetics of Four Dose Regimens of the Oral sGC Stimulator BAY1021189 Over 12 Weeks in Patients With Worsening Heart Failure and Preserved Ejection Fraction (HFpEF)
Status: Enrolling
Updated:  10/9/2015
Clinical Research Facility
mi
from
New Orleans, LA
Phase IIb Safety and Efficacy Study of Four Dose Regimens of BAY1021189 in Patients With Heart Failure and Preserved Ejection Fraction Suffering From Worsening Chronic Heart Failure (SOCRATES-PRESERVED)
A Randomized Parallel-group, Placebo-controlled, Double-blind, Multi-center Dose Finding Phase II Trial Exploring the Pharmacodynamic Effects, Safety and Tolerability, and Pharmacokinetics of Four Dose Regimens of the Oral sGC Stimulator BAY1021189 Over 12 Weeks in Patients With Worsening Heart Failure and Preserved Ejection Fraction (HFpEF)
Status: Enrolling
Updated: 10/9/2015
Clinical Research Facility
mi
from
New Orleans, LA
Click here to add this to my saved trials
Phase IIb Safety and Efficacy Study of Four Dose Regimens of BAY1021189 in Patients With Heart Failure and Preserved Ejection Fraction Suffering From Worsening Chronic Heart Failure (SOCRATES-PRESERVED)
A Randomized Parallel-group, Placebo-controlled, Double-blind, Multi-center Dose Finding Phase II Trial Exploring the Pharmacodynamic Effects, Safety and Tolerability, and Pharmacokinetics of Four Dose Regimens of the Oral sGC Stimulator BAY1021189 Over 12 Weeks in Patients With Worsening Heart Failure and Preserved Ejection Fraction (HFpEF)
Status: Enrolling
Updated:  10/9/2015
Clinical Research Facility
mi
from
Detroit, MI
Phase IIb Safety and Efficacy Study of Four Dose Regimens of BAY1021189 in Patients With Heart Failure and Preserved Ejection Fraction Suffering From Worsening Chronic Heart Failure (SOCRATES-PRESERVED)
A Randomized Parallel-group, Placebo-controlled, Double-blind, Multi-center Dose Finding Phase II Trial Exploring the Pharmacodynamic Effects, Safety and Tolerability, and Pharmacokinetics of Four Dose Regimens of the Oral sGC Stimulator BAY1021189 Over 12 Weeks in Patients With Worsening Heart Failure and Preserved Ejection Fraction (HFpEF)
Status: Enrolling
Updated: 10/9/2015
Clinical Research Facility
mi
from
Detroit, MI
Click here to add this to my saved trials
Phase IIb Safety and Efficacy Study of Four Dose Regimens of BAY1021189 in Patients With Heart Failure and Preserved Ejection Fraction Suffering From Worsening Chronic Heart Failure (SOCRATES-PRESERVED)
A Randomized Parallel-group, Placebo-controlled, Double-blind, Multi-center Dose Finding Phase II Trial Exploring the Pharmacodynamic Effects, Safety and Tolerability, and Pharmacokinetics of Four Dose Regimens of the Oral sGC Stimulator BAY1021189 Over 12 Weeks in Patients With Worsening Heart Failure and Preserved Ejection Fraction (HFpEF)
Status: Enrolling
Updated:  10/9/2015
Clinical Research Facility
mi
from
Detroit, MI
Phase IIb Safety and Efficacy Study of Four Dose Regimens of BAY1021189 in Patients With Heart Failure and Preserved Ejection Fraction Suffering From Worsening Chronic Heart Failure (SOCRATES-PRESERVED)
A Randomized Parallel-group, Placebo-controlled, Double-blind, Multi-center Dose Finding Phase II Trial Exploring the Pharmacodynamic Effects, Safety and Tolerability, and Pharmacokinetics of Four Dose Regimens of the Oral sGC Stimulator BAY1021189 Over 12 Weeks in Patients With Worsening Heart Failure and Preserved Ejection Fraction (HFpEF)
Status: Enrolling
Updated: 10/9/2015
Clinical Research Facility
mi
from
Detroit, MI
Click here to add this to my saved trials
Phase IIb Safety and Efficacy Study of Four Dose Regimens of BAY1021189 in Patients With Heart Failure and Preserved Ejection Fraction Suffering From Worsening Chronic Heart Failure (SOCRATES-PRESERVED)
A Randomized Parallel-group, Placebo-controlled, Double-blind, Multi-center Dose Finding Phase II Trial Exploring the Pharmacodynamic Effects, Safety and Tolerability, and Pharmacokinetics of Four Dose Regimens of the Oral sGC Stimulator BAY1021189 Over 12 Weeks in Patients With Worsening Heart Failure and Preserved Ejection Fraction (HFpEF)
Status: Enrolling
Updated:  10/9/2015
Clinical Research Facility
mi
from
Minneapolis, MN
Phase IIb Safety and Efficacy Study of Four Dose Regimens of BAY1021189 in Patients With Heart Failure and Preserved Ejection Fraction Suffering From Worsening Chronic Heart Failure (SOCRATES-PRESERVED)
A Randomized Parallel-group, Placebo-controlled, Double-blind, Multi-center Dose Finding Phase II Trial Exploring the Pharmacodynamic Effects, Safety and Tolerability, and Pharmacokinetics of Four Dose Regimens of the Oral sGC Stimulator BAY1021189 Over 12 Weeks in Patients With Worsening Heart Failure and Preserved Ejection Fraction (HFpEF)
Status: Enrolling
Updated: 10/9/2015
Clinical Research Facility
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Phase IIb Safety and Efficacy Study of Four Dose Regimens of BAY1021189 in Patients With Heart Failure and Preserved Ejection Fraction Suffering From Worsening Chronic Heart Failure (SOCRATES-PRESERVED)
A Randomized Parallel-group, Placebo-controlled, Double-blind, Multi-center Dose Finding Phase II Trial Exploring the Pharmacodynamic Effects, Safety and Tolerability, and Pharmacokinetics of Four Dose Regimens of the Oral sGC Stimulator BAY1021189 Over 12 Weeks in Patients With Worsening Heart Failure and Preserved Ejection Fraction (HFpEF)
Status: Enrolling
Updated:  10/9/2015
Clinical Research Facility
mi
from
Jackson, MS
Phase IIb Safety and Efficacy Study of Four Dose Regimens of BAY1021189 in Patients With Heart Failure and Preserved Ejection Fraction Suffering From Worsening Chronic Heart Failure (SOCRATES-PRESERVED)
A Randomized Parallel-group, Placebo-controlled, Double-blind, Multi-center Dose Finding Phase II Trial Exploring the Pharmacodynamic Effects, Safety and Tolerability, and Pharmacokinetics of Four Dose Regimens of the Oral sGC Stimulator BAY1021189 Over 12 Weeks in Patients With Worsening Heart Failure and Preserved Ejection Fraction (HFpEF)
Status: Enrolling
Updated: 10/9/2015
Clinical Research Facility
mi
from
Jackson, MS
Click here to add this to my saved trials
Phase IIb Safety and Efficacy Study of Four Dose Regimens of BAY1021189 in Patients With Heart Failure and Preserved Ejection Fraction Suffering From Worsening Chronic Heart Failure (SOCRATES-PRESERVED)
A Randomized Parallel-group, Placebo-controlled, Double-blind, Multi-center Dose Finding Phase II Trial Exploring the Pharmacodynamic Effects, Safety and Tolerability, and Pharmacokinetics of Four Dose Regimens of the Oral sGC Stimulator BAY1021189 Over 12 Weeks in Patients With Worsening Heart Failure and Preserved Ejection Fraction (HFpEF)
Status: Enrolling
Updated:  10/9/2015
Clinical Research Facility
mi
from
Omaha, NE
Phase IIb Safety and Efficacy Study of Four Dose Regimens of BAY1021189 in Patients With Heart Failure and Preserved Ejection Fraction Suffering From Worsening Chronic Heart Failure (SOCRATES-PRESERVED)
A Randomized Parallel-group, Placebo-controlled, Double-blind, Multi-center Dose Finding Phase II Trial Exploring the Pharmacodynamic Effects, Safety and Tolerability, and Pharmacokinetics of Four Dose Regimens of the Oral sGC Stimulator BAY1021189 Over 12 Weeks in Patients With Worsening Heart Failure and Preserved Ejection Fraction (HFpEF)
Status: Enrolling
Updated: 10/9/2015
Clinical Research Facility
mi
from
Omaha, NE
Click here to add this to my saved trials
Phase IIb Safety and Efficacy Study of Four Dose Regimens of BAY1021189 in Patients With Heart Failure and Preserved Ejection Fraction Suffering From Worsening Chronic Heart Failure (SOCRATES-PRESERVED)
A Randomized Parallel-group, Placebo-controlled, Double-blind, Multi-center Dose Finding Phase II Trial Exploring the Pharmacodynamic Effects, Safety and Tolerability, and Pharmacokinetics of Four Dose Regimens of the Oral sGC Stimulator BAY1021189 Over 12 Weeks in Patients With Worsening Heart Failure and Preserved Ejection Fraction (HFpEF)
Status: Enrolling
Updated:  10/9/2015
Clinical Research Facility
mi
from
Newark, NJ
Phase IIb Safety and Efficacy Study of Four Dose Regimens of BAY1021189 in Patients With Heart Failure and Preserved Ejection Fraction Suffering From Worsening Chronic Heart Failure (SOCRATES-PRESERVED)
A Randomized Parallel-group, Placebo-controlled, Double-blind, Multi-center Dose Finding Phase II Trial Exploring the Pharmacodynamic Effects, Safety and Tolerability, and Pharmacokinetics of Four Dose Regimens of the Oral sGC Stimulator BAY1021189 Over 12 Weeks in Patients With Worsening Heart Failure and Preserved Ejection Fraction (HFpEF)
Status: Enrolling
Updated: 10/9/2015
Clinical Research Facility
mi
from
Newark, NJ
Click here to add this to my saved trials
Phase IIb Safety and Efficacy Study of Four Dose Regimens of BAY1021189 in Patients With Heart Failure and Preserved Ejection Fraction Suffering From Worsening Chronic Heart Failure (SOCRATES-PRESERVED)
A Randomized Parallel-group, Placebo-controlled, Double-blind, Multi-center Dose Finding Phase II Trial Exploring the Pharmacodynamic Effects, Safety and Tolerability, and Pharmacokinetics of Four Dose Regimens of the Oral sGC Stimulator BAY1021189 Over 12 Weeks in Patients With Worsening Heart Failure and Preserved Ejection Fraction (HFpEF)
Status: Enrolling
Updated:  10/9/2015
Clinical Research Facility
mi
from
Buffalo, NY
Phase IIb Safety and Efficacy Study of Four Dose Regimens of BAY1021189 in Patients With Heart Failure and Preserved Ejection Fraction Suffering From Worsening Chronic Heart Failure (SOCRATES-PRESERVED)
A Randomized Parallel-group, Placebo-controlled, Double-blind, Multi-center Dose Finding Phase II Trial Exploring the Pharmacodynamic Effects, Safety and Tolerability, and Pharmacokinetics of Four Dose Regimens of the Oral sGC Stimulator BAY1021189 Over 12 Weeks in Patients With Worsening Heart Failure and Preserved Ejection Fraction (HFpEF)
Status: Enrolling
Updated: 10/9/2015
Clinical Research Facility
mi
from
Buffalo, NY
Click here to add this to my saved trials